A-Ying Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A-Ying Ma has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Chao Gao
Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
2 shared publications - Ai-Wu Ke
Zhongshan Hospital 1 Liver Cancer Institute Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education Shanghai, China
1 shared publication Hui Zou
Department of Gastroenterology, Jingdezhen hospital of Traditional Chinese Medicine
1 shared publicationJieyun Zou
Fudan University
1 shared publicationLi Yuan
Zhongshan Hospital Fudan University Department of Liver Surgery
1 shared publicationRuihua Zhong
Fudan University
1 shared publication
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- p. OF1-OF16
The PON1–NDUFA4 Axis Maintains Mitochondrial Respiratory Fitness and Drives Lenvatinib Tolerance in Hepatocellular Carcinoma
Metabolic plasticity driven by mitochondrial oxidative phosphorylation (OXPHOS) is increasingly recognized as a key determinant of therapeutic tolerance in hepatocellular carcinoma (HCC), but the upstream regulators that preserve electron transport chain stability during treatment remain poorly defined. In this study, we identified paraoxonase 1 (PON1) as a clinically relevant regulator of mitochondrial metabolism and lenvatinib response in HCC. PON1 was markedly upregulated in HCC and independently associated with poor overall and recurrence-free survival. Functionally, PON1 promoted tumor growth and conferred robust tolerance to lenvatinib. Mechanistically, PON1 directly interacted with and stabilized NDUFA4, a key component required for complex IV assembly, thereby maintaining mitochondrial membrane potential, complex IV integrity, and OXPHOS-dependent adenosine triphosphate production while limiting reactive oxygen species accumulation. Genetic silencing of PON1 or NDUFA4 impaired mitochondrial respiration, increased oxidative stress, and restored lenvatinib sensitivity in HCC cells and xenograft models. Structure-guided virtual screening identified the Food and Drug Administration–approved CFTR corrector lumacaftor as a potent modulator of PON1 that disrupted the PON1–NDUFA4 interaction and enhanced the antitumor efficacy of lenvatinib in vivo. These findings identify the PON1–NDUFA4 axis as a previously unrecognized metabolic vulnerability that sustains mitochondrial respiratory fitness and lenvatinib resistance in HCC. Targeting mitochondrial protein-stabilizing mechanisms such as PON1–NDUFA4 may offer a broadly applicable strategy for overcoming therapy resistance in liver cancer and other aggressive malignancies. Implications: These findings establish mitochondrial protein stabilization as an actionable therapeutic vulnerability and provide a rationale for combination strategies to overcome targeted therapy resistance in HCC.
- 2 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- p. OF1-OF16
Open AccessThe PON1–NDUFA4 Axis Maintains Mitochondrial Respiratory Fitness and Drives Lenvatinib Tolerance in Hepatocellular Carcinoma
Metabolic plasticity driven by mitochondrial oxidative phosphorylation (OXPHOS) is increasingly recognized as a key determinant of therapeutic tolerance in hepatocellular carcinoma (HCC), but the upstream regulators that preserve electron transport chain stability during treatment remain poorly defined. In this study, we identified paraoxonase 1 (PON1) as a clinically relevant regulator of mitochondrial metabolism and lenvatinib response in HCC. PON1 was markedly upregulated in HCC and independently associated with poor overall and recurrence-free survival. Functionally, PON1 promoted tumor growth and conferred robust tolerance to lenvatinib. Mechanistically, PON1 directly interacted with and stabilized NDUFA4, a key component required for complex IV assembly, thereby maintaining mitochondrial membrane potential, complex IV integrity, and OXPHOS-dependent adenosine triphosphate production while limiting reactive oxygen species accumulation. Genetic silencing of PON1 or NDUFA4 impaired mitochondrial respiration, increased oxidative stress, and restored lenvatinib sensitivity in HCC cells and xenograft models. Structure-guided virtual screening identified the Food and Drug Administration–approved CFTR corrector lumacaftor as a potent modulator of PON1 that disrupted the PON1–NDUFA4 interaction and enhanced the antitumor efficacy of lenvatinib in vivo. These findings identify the PON1–NDUFA4 axis as a previously unrecognized metabolic vulnerability that sustains mitochondrial respiratory fitness and lenvatinib resistance in HCC. Targeting mitochondrial protein-stabilizing mechanisms such as PON1–NDUFA4 may offer a broadly applicable strategy for overcoming therapy resistance in liver cancer and other aggressive malignancies. Implications: These findings establish mitochondrial protein stabilization as an actionable therapeutic vulnerability and provide a rationale for combination strategies to overcome targeted therapy resistance in HCC.
- Open Access
- 20 September 2024
- Published by Springer Nature in Research Square
Anti-inflammatory Effect of Nestorone in a Lipopolysaccharide-induced Acute Lung Injury Model through Regulation of the TLR-4/Myd88/NF-κB Signaling Pathway
Progesterone plays a crucial and indispensable role in regulating immunity and attenuating inflammation. Nestorone ® (NES, segesterone acetate) is a steroidal progestin and a 19-norprogesterone derivative with no -CH3 group radical at the 6-position. Here, we showed that NES enhanced the viability of lipopolysaccharide (LPS)-stimulated THP-1 cell-derived macrophages, potently inhibiting both arms of the Toll-like receptor 4 (TLR-4) signaling cascade triggered by LPS, especially the TLR-4/MyD88/NF-κB pathway. In addition, NES exerted an anti-inflammatory effect by significantly decreasing the secretion of inflammatory cytokines and chemokines in type II alveolar epithelial A549 cells and THP-1 cell-derived macrophages stimulated by LPS. Furthermore, we evaluated the potential of pre-treatment with NES 2 hours before LPS treatment to rescue the lung from acute LPS-induced injury, using an LPS-induced acute lung injury (ALI) mouse model. In this study NES alleviated lung inflammation and damage through reducing leukocyte infiltration and inflammatory cytokines in mouse bronchoalveolar lavage fluid (BALF) and lung tissues. Interestingly, we found that NES at 1 mg/kg was superior to 0.1 or 10 mg/kg or to dexamethasone (DEX, 5 mg/kg) in prolonging survival in mice experiencing lethal LPS-induced injury, decreasing acute lung inflammation, and alleviating diffuse alveolar damage in the lungs of C57 mice. Overall, our study suggested that concentration was one of the key factors in determining the anti-inflammatory potency of NES, and therefore NES may serve as a promising novel therapeutic agent to treat pulmonary inflammatory diseases such as ALI/acute respiratory distress syndrome (ARDS) by modulating TLR-4 signaling.
- 20 September 2024
- Published by Springer Nature in Research Square
Open AccessAnti-inflammatory Effect of Nestorone in a Lipopolysaccharide-induced Acute Lung Injury Model through Regulation of the TLR-4/Myd88/NF-κB Signaling Pathway
Progesterone plays a crucial and indispensable role in regulating immunity and attenuating inflammation. Nestorone ® (NES, segesterone acetate) is a steroidal progestin and a 19-norprogesterone derivative with no -CH3 group radical at the 6-position. Here, we showed that NES enhanced the viability of lipopolysaccharide (LPS)-stimulated THP-1 cell-derived macrophages, potently inhibiting both arms of the Toll-like receptor 4 (TLR-4) signaling cascade triggered by LPS, especially the TLR-4/MyD88/NF-κB pathway. In addition, NES exerted an anti-inflammatory effect by significantly decreasing the secretion of inflammatory cytokines and chemokines in type II alveolar epithelial A549 cells and THP-1 cell-derived macrophages stimulated by LPS. Furthermore, we evaluated the potential of pre-treatment with NES 2 hours before LPS treatment to rescue the lung from acute LPS-induced injury, using an LPS-induced acute lung injury (ALI) mouse model. In this study NES alleviated lung inflammation and damage through reducing leukocyte infiltration and inflammatory cytokines in mouse bronchoalveolar lavage fluid (BALF) and lung tissues. Interestingly, we found that NES at 1 mg/kg was superior to 0.1 or 10 mg/kg or to dexamethasone (DEX, 5 mg/kg) in prolonging survival in mice experiencing lethal LPS-induced injury, decreasing acute lung inflammation, and alleviating diffuse alveolar damage in the lungs of C57 mice. Overall, our study suggested that concentration was one of the key factors in determining the anti-inflammatory potency of NES, and therefore NES may serve as a promising novel therapeutic agent to treat pulmonary inflammatory diseases such as ALI/acute respiratory distress syndrome (ARDS) by modulating TLR-4 signaling.